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A b s t r a c t
Introduction: The CHA2DS2-VASc and R2-CHA2DS2-VASc scores were initially designed to evaluate the risk of cerebrovascular 
events in patients with atrial fibrillation. However, these scales consist of parameters which are well known as general risk factors 
for cardiovascular events. 
Aim: To assess the role of the CHA
2DS2-VASc and R2-CHA2DS2-VASc scores in predicting outcome of patients with myocardial 
infarction (MI).
Material and methods: We enrolled 212 consecutive patients with both ST-elevation and non-ST-elevation MI referred for pri-
mary percutaneous coronary intervention (PCI). Patients were divided into two groups depending on the CHA
2DS2-VASc score: ≤ 3 
(low score) and > 3 points (high score). 
Results: The group with a CHA
2DS2-VASc score > 3 points consisted of 93 (44%) patients. Follow-up was available in 200 (94.3%) 
patients with median duration of 10 (Q1: 6; Q3: 13) months. During the follow-up all-cause mortality was greater in patients from 
the high score group (21%) compared to patients with lower scores (8%) (p = 0.009). Recurrent MI was found in 4% of patients 
from the low score group and in 13% of patients from the high score group (p = 0.024). The combined endpoint of cardiovascular 
mortality, recurrent non-fatal MI and non-fatal stroke occurred in 13% of lower score patients and in 30% of patients with a score 
> 3 points (p = 0.002). In a Cox regression model both scores were predictors of all-cause mortality with a hazard ratio of 1.31 per 
1 point increase for the CHA
2DS2-VASc score (p = 0.004) and 1.36 for the R2-CHA2DS2-VASc score (p < 0.001). 
Conclusions: The CHA
2DS2-VASc and R2-CHA2DS2-VASc scores predict in-hospital and post-discharge outcome in patients with 
acute MI undergoing primary PCI.
Key words: acute coronary syndrome, risk, mortality.
S u m m a r y
In the present study we demonstrate that simple assessment with the CHA2DS2-VASc score predicts outcome in patients 
with acute myocardial infarction. In receiver-operating characteristics analysis, we established a cut-off value of 3 points for 
the CHA
2DS2-VASc score for predicting clinical events during follow-up. Patients with CHA2DS2-VASc > 3 had higher rates of 
all-cause mortality, re-infarction and combined endpoint (cardiovascular death, re-infarction and stroke). Presence of heart 
failure was associated with the highest hazard ratio for predicting all-cause mortality. Additional renal function assessment 
(R
2-CHA2DS2-VASc score) was associated with an increase in the predictive value for all-cause mortality. 
Introduction
Risk assessment is crucial in the decision-making 
process in patients with cardiovascular diseases. Identi-
fication of high-risk individuals allows one to implement 
tailored aggressive therapy and improve their outcome. 
The CHA
2DS2-VASc was originally designed and validated 
for evaluating the probability of cerebrovascular events 
in patients with atrial fibrillation (AF) [1–6]. It is simple 
and broadly used in clinical practice due to the growing 
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number of patients with AF. However, the CHA2DS2-VASc 
score consists of several parameters, namely heart fail-
ure, age, gender, history of arterial hypertension, dia-
betes mellitus, vascular disease and stroke, which are 
well-known predictors of cardiovascular events [2]. The 
R2-CHA2DS2-VASc scale also includes renal function as-
sessment [4]. A  correlation between higher CHA2DS2-
VASc score and increased mortality of patients with myo-
cardial infarction (MI) has been found in several analyses 
[7, 8]. However, the impact of this scale on in-hospital 
outcome and rates of recurrent MI in patients hospital-
ized with acute MI remains unclear. 
Aim
To assess the value of CHA2DS2-VASc and R2-CHA2DS2-
VASc scores as predictors of outcome in patients with 
acute MI.
Material and methods
Study population 
The present study is a retrospective analysis of consec-
utive patients diagnosed with MI who underwent primary 
percutaneous coronary intervention (PCI) in a single cen-
ter. Both ST-segment elevation and non-ST-segment ele-
vation MI patients were included. For better homogene-
ity of the study group we excluded patients: with MI who 
were not referred to coronary angiography, with MI with 
non-obstructive coronary arteries and patients referred for 
coronary artery bypass grafting. The study was approved 
by the institutional ethical board. The CHA2DS2-VASc 
score was calculated for all patients regardless of pres-
ence of AF by adding 1 point each for presence of con-
gestive heart failure, history of arterial hypertension, di-
abetes, vascular disease, age ≥ 65 years, female gender, 
and 2 points each for age ≥ 75 years and history of stroke 
or transient ischemic attack (TIA). The R2-CHA2DS2-VASc 
score was assessed by adding 2 extra points for renal 
function impairment, which was defined by glomerular 
filtration rate (GFR) ≤ 60 ml/min/1.73 m2 calculated with 
the MDRD formula [4]. History of arterial hypertension, 
diabetes, vascular disease and stroke was assessed via 
the patient’s medical records. Vascular disease included 
previous MI, peripheral artery disease or aortic plaque. 
Congestive heart failure was defined as left ventricular 
ejection fraction (LVEF) < 40%, measured by echocardiog-
raphy with signs and symptoms of right or left ventricle 
failure [1].
Follow-up data were obtained from telephone inter-
views and medical records in the hospital electronic da-
tabase. The rates of all-cause and cardiovascular death, 
recurrent MI and stroke were assessed. Cardiovascular 
mortality included death resulting from acute MI, stent 
thrombosis, heart failure, stroke, cardiovascular proce-
dures, sudden cardiac death or other known cardiovascu-
lar causes. Combined endpoint was defined as a combi-
nation of cardiovascular mortality, non-fatal recurrent MI 
and non-fatal stroke. Non-fatal MI and non-fatal stroke 
were defined as events with survival until hospital dis-
charge. Long-term analysis of clinical events also includ-
ed those which occurred during the in-hospital course. 
Patients’ characteristics and rates of clinical events 
were analyzed in relation to CHA2DS2-VASc and R2-CHA2DS2-
VASc score categories with cut-off values established by 
evaluating the area under the curve (AUC) in receiver-oper-
ating characteristics analysis (ROC).
Statistical analysis
Quantitative variables were described using means 
with standard deviation (for normal distribution of data) 
or median with interquartile range (for non-normal dis-
tribution of data). Categorical variables were presented 
with counts and as percentages. The Mann-Whitney 
U test (for non-normal distribution of data) was applied 
for continuous variables. The χ2 test was used for cat-
egorical (nominal and dichotomous) variables. Survival 
was estimated using the Kaplan-Meier method according 
to CHA2DS2-VASc and R2-CHA2DS2-VASc score categories 
with the log-rank test for full follow-up time available. 
Adequacy of CHA2DS2-VASc and R2-CHA2DS2-VASc scores 
for predicting clinical outcome was assessed in ROC anal-
ysis for full follow-up time available. Univariate and mul-
tivariate Cox regression models were used to investigate 
the effect of each component of the scores for predicting 
all-cause mortality. The level of statistical significance 
was set at an α value < 0.05. All analyses were performed 
with SPSS Statistics 24 (IBM, Inc. NY, USA).
Results
Study population and in-hospital 
characteristics
A total of 212 consecutive patients with MI, who un-
derwent primary PCI between September 2016 and July 
2017, entered the study. The median CHA2DS2-VASc score 
was 3 (Q1: 2; Q3: 4.5) points. For the R2-CHA2DS2-VASc 
score the median value was 4 (Q1: 2; Q3: 6). The group 
with a  high CHA2DS2-VASc score (> 3) consisted of 93 
(44%) patients, whereas a CHA2DS2-VASc score ≤ 3 points 
was found in the remaining 119 (56%) patients. Baseline 
clinical characteristics are shown in Table I. There were 
no significant differences in the type of MI (ST-elevation 
and non-ST-elevation) between groups. Patients with 
a high CHA2DS2-VASc score were by definition older and 
more often had a  history of diabetes mellitus, arterial 
hypertension, vascular disease, heart failure and stroke. 
During hospital stay, patients from the high score group 
more often had respiratory tract infections and required 
systemic antibiotics. It resulted in longer hospitalization 
duration and more frequent transfers to general medi-
cine units for treatment continuation. Administration of 
loop diuretics and aldosterone antagonists was also more 
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frequent in those patients. In our analysis baseline GFR 
was significantly lower in patients with a CHA2DS2-VASc 
score > 3. Atrial fibrillation (including both past medical 
history and new onset during hospitalization) was more 
frequent in patients from the high score group (Table I). 
In patients with a CHA2DS2-VASc score > 3, higher in-hos-
pital mortality was observed, but without statistical sig-
nificance. No cases of recurrent MI were reported during 
index hospitalization in both groups (Table II).
Long-term clinical outcome
Follow-up was obtained in 200 (94.3%) patients. 
Median duration of follow-up was 10 (Q1: 6; Q3: 13) 
months. Follow-up data were not available in 6% of pa-
tients from the low score group and in 5% of patients 
with a  higher score value (p = 1). In Table II we show 
rates of events occurring during follow-up observation 
(presented as the sum of events occurring during in-
dex hospitalization and follow-up). All-cause mortality 
was significantly greater in patients from the high score 
group (21%) compared to patients with lower scores (8%) 
(p = 0.009). There was also higher cardiovascular mortal-
ity in patients with CHA2DS2-VASc > 3 points (15% com-
pared to 8%), although without statistical significance 
(p = 0.19). Among 8 patients from the high score group, 
who died after index hospitalization, 2 patients died due 
to cardiovascular causes (recurrent MI and heart failure), 
2 patients died from cancer disease and in the remain-
Table I. Baseline and in-hospital course characteristics
Parameter All patients 
(n = 212)
CHA2DS2-VASc ≤ 3 
(n = 119)
CHA2DS2-VASc > 3 
(n = 93)
P-value
Age [years]* 67 ±12 61 (Q1: 56; Q3: 68) 76 (Q1: 69; Q3: 83) < 0.001
Male gender* 141 (66%) 95 (80%) 46 (49%) < 0.001
LVEF (%)* 48 (Q1: 40; Q3: 55) 52 (Q1: 45; Q3: 60) 40 (Q1: 33; Q3: 50) < 0.001
Arterial hypertension* 167 (79%) 81 (68%) 86 (92%) < 0.001
Vascular disease* 87 (41%) 31 (26%) 56 (60%) < 0.001
Stroke history* 18 (8%) 1 (1%) 17 (18%) < 0.001
Diabetes* 77 (36%) 26 (22%) 51 (55%) < 0.001
ST-segment elevation MI 65 (31%) 37 (31%) 28 (30%) 1.0
Culprit in LAD 78 (37%) 42 (35%) 36 (39%) 0.67
Multi-vessel PCI 76 (36%) 46 (39%) 30 (32%) 0.39
Staged revascularization 46 (22%) 30 (25%) 16 (17%) 0.18
Baseline serum creatinine [µmol/l] 83 (Q1: 69; Q3: 107) 75 (Q1: 67; Q3: 88) 95 (Q1: 76; Q3: 132) < 0.001
GFR ≤ 60 ml/min/1.73 m2 64 (30%) 16 (13%) 48 (52%) < 0.001
AF (history of and new onset) 37 (17%) 11 (9%) 26 (28%) 0.001
ACEI/ARB 171 (81%) 101 (86%) 70 (75%) 0.05
b-Blockers 173 (82%) 100 (85%) 73 (78%) 0.2
Statins 204 (96%) 114 (97%) 90 (97%) 1.0
Loop diuretics 79 (37%) 23 (20%) 56 (60%) < 0.001
Aldosterone antagonists 46 (22%) 10 (8%) 36 (39%) < 0.001
RBC transfusion 8 (4%) 4 (3%) 4 (4%) 0.73
Ventricular arrhythmia 17 (8%) 8 (7%) 9 (10%) 0.45
Hospitalization length [days] 7 (Q: 5; Q3: 9) 7 (Q1: 5; Q3: 8) 8 (Q1: 6; Q3: 11) 0.002
Respiratory tract infection 33 (16%) 8 (7%) 25 (27%) < 0.001
Treatment continuation in  
an internal medicine unit
12 (6%) 1 (1%) 11 (12%) 0.001
LVEF – left ventricular ejection fraction, MI – myocardial infarction, LAD – left anterior descending artery, PCI – percutaneous coronary intervention, GFR – glomerular 
filtration rate, AF – atrial fibrillation, ACEI – angiotensin converting enzyme inhibitors, ARB – angiotensin receptor blocker, RBC – red blood cell; *parameters included 
in the CHA
2
DS
2
-VASc score.
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ing 4 patients we could not establish the exact cause 
of death in a telephone interview and these cases were 
treated as non-cardiovascular deaths. Recurrent MI was 
found in 4% of patients from the low score group and in 
13% of patients from the high score group (p = 0.024). 
The combined endpoint occurred in 13% of patients with 
low scores and in 30% of patients with a score > 3 points 
(p = 0.002). Kaplan-Meier survival analysis showed signif-
icant differences for all-cause mortality, recurrent MI and 
combined endpoint between patients with higher and 
lower CHA
2DS2-VASc and the R2-CHA2DS2-VASc scores 
(Figure 1). In a Cox regression model both scores were 
significant predictors of all-cause mortality with a haz-
ard ratio of 1.31 per 1 point increase for the CHA
2DS2-
VASc score (95% CI: 1.1–1.6, p = 0.004) and 1.36 for the 
R
2-CHA2DS2-VASc score (95% CI: 1.2–1.6, p < 0.001). In 
Table III we present the effect of each component of the 
scores on all-cause mortality. In multivariate analysis of 
R
2-CHA2DS2-VASc score components, heart failure and re-
nal insufficiency were significant predictors of all-cause 
mortality. In multivariate analysis of CHA
2DS2-VASc score 
components only the occurrence of heart failure was 
a significant predictor of all-cause mortality. Congestive 
heart failure was associated with the highest hazard ra-
tio, both in an unadjusted and adjusted Cox regression 
model. In Table IV and Figure 2 we show ROC analysis for 
CHA
2DS2-VASc and R2-CHA2DS2-VASc scores with cut-off 
values for both scales for predicting clinical events. The 
R
2-CHA2DS2-VASc presented a fair value (AUC > 0.7) for 
predicting all-cause and cardiovascular mortality and the 
combined endpoint, whereas the CHA
2DS2-VASc present-
ed AUC values < 0.7 for predicting clinical events. 
Discussion 
The major finding of our study is that even simpli-
fied evaluation with the CHA
2DS2-VASc scale could 
identify patients with acute MI at a higher risk of worse 
clinical outcome. At the same time, patients with a low 
CHA2DS2-VASc score had a good outcome with a  rela-
tively small number of events after discharge.
Early risk stratification helps clinicians in defin-
ing a  patient’s prognosis and managing the treatment 
strategy. Several scales have been developed to identify 
high-risk patients who may benefit most from early ag-
gressive therapies, including the Global Registry of Acute 
Coronary Events, Thrombolysis in Myocardial Infarction, 
and Primary Angioplasty in Myocardial Infarction [9–12]. 
However, these scales are complex and require special 
online calculators. They are well validated in clinical 
trials but rarely used in everyday clinical practice. The 
Table II. In-hospital and long-term outcome
Parameter CHA2DS2-VASc ≤ 3 (n = 119) CHA2DS2-VASc > 3 (n = 93) P-value
In-hospital outcome:
All-cause mortality 10 (8%) 12 (13%) 0.36
Cardiovascular mortality 10 (8%) 12 (13%) 0.36
All recurrent MI 0 0
Non-fatal recurrent MI 0 0
All stroke 0 4 (4%) 0.036
Non-fatal stroke 0 2 (2%) 0.19
Combined endpoint 10 (8%) 14 (15%) 0.19
Stent thrombosis 0 0
Long-term outcome:
All-cause mortality 10 (8%) 20 (21%) 0.009
Cardiovascular mortality 10 (8%) 14 (15%) 0.19
All recurrent MI 5 (4%) 12 (13%) 0.024
Non-fatal recurrent MI 5 (4%) 11 (12%) 0.064
All stroke (1%) 5 (5%) 0.09
Non-fatal stroke (1%) 3 (3%) 0.32
Combined endpoint 15 (13%) 28 (30%) 0.002
Stent thrombosis 0 1 (1%) 0.44
MI – myocardial infarction.
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Figure 1. Kaplan-Meier analysis for general survival (A), survival without recurrent myocardial infarction (B), 
survival without combined endpoint (C) in relation to CHA2DS2-VASc and to R2-CHA2DS2-VASc score categories 
during follow-up
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CHA2DS2-VASc score was designed for assessing the risk 
of thromboembolic events in patients with AF [1–3]. It is 
very simple and broadly known and used by clinicians. 
Several studies have confirmed the usefulness of this 
score in predicting outcomes, including in patients who 
do not have AF [13–17]. The impact of the CHA2DS2-VASc 
score on clinical outcomes in patients with MI has been 
reported. In a study on over 13,000 patients with acute 
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Table III. Effect of components of the (R2-)CHA2DS2-VASc scores on all-cause mortality during full follow-up 
time available
Parameter Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Age ≥ 65 years 0.79 0.3–1.8 0.59 0.9 0.3–3.0 0.87
Age ≥ 75 years 1.70 1.2–2.4 0.004 1.01 0.6–1.8 0.97
Female gender 1.61 0.8–3.3 0.20 1.07 0.4–2.6 0.87
Heart failure 7.90 3.3–19.0 < 0.001 4.6 1.7–12.0 0.002
Hypertension 0.46 0.2–1.0 0.045 0.39 0.1–1.1 0.07
History of stroke 1.13 0.6–2.0 0.69 0.88 0.4–1.8 0.73
Vascular disease 1.08 0.5–2.2 0.84 1.1 0.5–2.5 0.85
Diabetes 1.82 0.9–3.7 0.10 1.89 0.8–4.5 0.16
GFR ≤ 60 ml/min/1.73 m2 2.9 1.9–4.5 < 0.001 2.1 1.2–3.6 0.008
GFR – glomerular filtration rate.
Table IV. Receiver operating characteristics analysis of the CHA2DS2-VASc and R2-CHA2DS2-VASc scores for pre-
dicting clinical events during full follow-up time available
Variable Cut-off value Sensitivity Specificity AUC P-value 95% CI
CHA
2
DS
2
-VASc:
All-cause mortality 3 0.67 0.6 0.67 0.003 0.6–0.8
Cardiac mortality 3 0.58 0.58 0.61 0.088 0.5–0.7
All recurrent MI 3 0.71 0.59 0.62 0.11 0.5–0.8
Non-fatal recurrent MI 3 0.69 0.58 0.6 0.17 0.4–0.8
Combined endpoint 3 0.65 0.62 0.64 0.004 0.6–0.7
R
2
-CHA
2
DS
2
-VASc:
All-cause mortality 4 0.7 0.71 0.76 < 0.001 0.7–0.9
Cardiac mortality 4 0.62 0.69 0.72 < 0.001 0.6–0.8
All recurrent MI 3 0.71 0.51 0.6 0.15 0.5–0.8
Non-fatal recurrent MI 3 0.69 0.51 0.59 0.25 0.4–0.7
Combined endpoint 3 0.79 0.56 0.7 < 0.001 0.6–0.8
MI – myocardial infarction.
coronary syndrome (ACS), those with a high (> 5 points) 
or intermediate (2–3 points) CHA2DS2-VASc score had sig-
nificantly higher 1-year mortality [7]. In another study on 
647 ST-elevation MI patients, those with a CHA
2DS2-VASc 
score ≥ 3 had greater in-hospital and 6-month mortal-
ity [8]. In 2014, Lau et al. showed that CHA
2DS2-VASc 
score > 3 is associated with increased risk of ischemic 
stroke in MI patients [18]. A cut-off value for CHA
2DS2-
VASc score for predicting adverse clinical outcome in the 
MI population has not been established. In our analy-
sis, the optimal cut-off value for predicting clinical end-
points was 3 for the CHA
2DS2-VASc score and 4 for the 
R
2-CHA2DS2-VASc scale. A study conducted by Podolecki 
et al. on 2647 patients with acute MI showed that 1 point 
increase in the CHA
2DS2-VASc score is associated with 
41% increase in stroke risk and 23% increase in mortal-
ity [19]. Some studies suggest even better performance 
of the CHA
2DS2-VASc score for predicting cardiovascular 
events in those patients with MI who do not have AF [20]. 
Barra et al. showed that CHA
2DS2-VASc score with addi-
tional renal function assessment predicts the occurrence 
of post-discharge ischemic stroke and all-cause mortality 
in a  cohort of patients with MI [21]. A Polish study on 
over 2000 patients with ACS showed better prognostic 
Michał Węgiel et al. (R
2
)-CHA
2
DS
2
-VASc score in AMI
397Advances in Interventional Cardiology 2018; 14, 4 (54)
1.0
0.8
0.6
0.4
0.2
0
 0 0.2 0.4 0.6 0.8 1.0
           1-Specificity
Se
ns
it
iv
it
y
Figure 2. Receiver operating characteristic curves 
for CHA2DS2-VASc and R2-CHA2DS2-VASc scores 
for predicting all-cause mortality during full fol-
low-up time available
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value of the R2-CHA2DS2-VASc score compared to the 
conventional CHA2DS2-VASc scale for predicting all-cause 
mortality [22]. In our study, ROC analysis showed an AUC 
value of 0.67 for the CHA
2DS2-VASc score and 0.76 for the 
R2-CHA2DS2-VASc score for predicting all-cause mortality. 
The CHA2DS2-VASc score however has some limita-
tions. It does not take into account several parameters 
such as cardiac biomarkers or hemodynamic status. On 
the other hand, all parameters included in the score are 
established risk factors of adverse clinical outcome in 
patients with MI [8]. In our analysis, congestive heart 
failure was associated with the highest hazard ratio for 
all-cause mortality. Interestingly, a history of arterial hy-
pertension seems to reduce the risk of mortality both in 
univariate and multivariate analysis (HR < 1). A possible 
explanation might be less frequent reporting of history of 
hypertension in patients admitted in a critical condition.
Study limitations
The present study is a  retrospective single-center 
analysis but represents real-world data as consecutive 
MI patients undergoing primary PCI were enrolled. The 
sample size was relatively small and the results allow for 
hypothesis generation only and planning of larger pro-
spective studies. The follow-up was also not completed 
in 100% of patients, yet the proportion of lacking obser-
vations was equal in both groups. 
Conclusions
The CHA2DS2-VASc score value > 3 points predicts 
poorer in-hospital and post-discharge outcome in pa-
tients with acute MI undergoing primary PCI. At the 
same time, patients with a low CHA
2DS2-VASc score have 
a good outcome with a relatively small number of events 
after discharge. 
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